Pharmacia Axert
Executive Summary
Regulatory decision on migraine treatment almotriptan expected in second quarter. Pharmacia received an FDA "approvable" letter Dec. 20, 2000 (1"The Pink Sheet" Jan. 1, In Brief)
You may also be interested in...
Pharmacia Axert
FDA issues "approvable" letter for the migraine treatment almotriptan Dec. 20. The NDA for the selective serotonin 5-HT receptor agonist was submitted Dec. 17, 1999
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials